サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1551569

原発性硬化性胆管炎治療の世界市場

Primary Sclerosing Cholangitis Treatment
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 285 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.96円
原発性硬化性胆管炎治療の世界市場
出版日: 2024年09月10日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 285 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

原発性硬化性胆管炎治療の世界市場は2030年までに2億2,010万米ドルに達する見込み

2023年に1億8,570万米ドルと推定される原発性硬化性胆管炎治療の世界市場は、分析期間2023-2030年にCAGR 2.5%で成長し、2030年には2億2,010万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである経口投与は、CAGR 2.8%を記録し、分析期間終了時には1億6,950万米ドルに達すると予測されます。非経口投与セグメントの成長率は、分析期間中CAGR 1.6％と推定されます。

米国市場は5,060万米ドルと推定、中国はCAGR 5.0％で成長予測

米国の原発性硬化性胆管炎治療市場は2023年に5,060万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4,390万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは5.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.6%と1.8%と予測されています。欧州では、ドイツがCAGR 1.2%で成長すると予測されています。

世界の原発性硬化性胆管炎治療市場- 主要動向と促進要因まとめ

原発性硬化性胆管炎とは何か？

原発性硬化性胆管炎（PSC）は、胆管の炎症と瘢痕化を特徴とする慢性進行性肝疾患であり、肝障害や最終的な肝不全につながる可能性があります。PSCの正確な原因は不明ですが、自己免疫疾患と関連することが多く、炎症性腸疾患（IBD）と強い相関があります。PSCの症状には黄疸、かゆみ、腹痛、倦怠感などがあり、肝障害が顕著になるまで静かに進行することが多いです。PSCの治療は主に、症状の管理、病気の進行の抑制、合併症への対処に重点を置く。肝機能を改善し、病気の進行を遅らせるために、ウルソデオキシコール酸（UDCA）などの薬剤が一般的に使用されます。PSCが肝不全に至った場合には、決定的な治療法として肝移植が考慮されます。しかし、PSCは複雑であり、他の疾患との関連もあるため、この疾患の管理には、個々の患者のニーズに合わせた包括的かつ集学的なアプローチが必要です。

原発性硬化性胆管炎治療における最新の進歩とは？

原発性硬化性胆管炎（PSC）の治療における最近の進歩は、新規治療と個別化治療戦略による患者の転帰の改善に焦点を当てています。原発性硬化性胆管炎の基礎メカニズムに関する新たな研究により、免疫系を調節し、胆管内の炎症を抑えることを目的とした標的治療薬が開発されました。臨床試験では、オベチコール酸のような薬剤の有効性が検討されています。オベチコール酸は、PSC患者における肝臓の炎症と線維化の抑制に有望であることが示されています。さらに、PSCの遺伝的・分子的基盤の解明が進み、個人の遺伝的プロファイルや疾患の特徴に基づいてより個別化された治療計画を可能にする精密医療への道が開かれつつあります。また、治療効果を高め、PSCの複雑な症例に対応するために、従来の薬剤と新しい薬剤を組み合わせた併用療法の役割も検討されています。これらの進展は、この課題であるPSCを管理するための、より効果的で個別化された治療法への大きな転換を意味します。

ライフスタイルの変化と支持療法はPSC管理にどのように影響するか？

原発性硬化性胆管炎（PSC）の管理には、薬物治療に加え、生活習慣の改善と支持療法が重要な役割を果たします。肝臓の健康をサポートし、症状を管理するために、吸収不良や栄養欠乏のリスクを軽減するための低脂肪食など、食事の変更がしばしば推奨されます。炎症性腸疾患（IBD）などの関連疾患の定期的なモニタリングと管理は、全身の健康を最適化し、PSCに関連する合併症を軽減するために不可欠です。かゆみを抑える薬物療法、ビタミン補給、骨粗鬆症や糖尿病などの合併症の治療などの支持療法も、包括的な治療には不可欠です。患者教育や心理的支援は、PSCのような慢性疾患を管理する上で重要な側面であり、患者が感情的・身体的課題に対処できるよう支援します。肝臓病専門医、消化器病専門医、栄養士、その他の専門家が協力することで、PSCを管理し、患者の生活の質を向上させるための総合的なアプローチが可能になります。

原発性硬化性胆管炎治療市場の成長を促すものは何か？

原発性硬化性胆管炎（PSC）治療市場の成長は、いくつかの要因によってもたらされます。研究開発の進歩は主要な貢献要因であり、PSCの根本的な病態に対処するための新たな治療標的の特定と新規薬剤の開発に焦点を当てた研究が進行中です。PSCの有病率の増加や医療従事者の間でこの疾患に対する認識が高まっていることが、治療選択肢の改善に対する需要に拍車をかけています。製薬企業による臨床試験の増加や医薬品開発への投資は、PSCに対するより効果的な治療法やより優れた管理戦略の必要性を反映しています。さらに、ヘルスケアへのアクセスが拡大し、肝臓専門センターが利用できるようになったことは、より多くの患者に高度な治療や集学的治療を提供することで市場の成長に寄与しています。また、個別化医療や精密治療を推進する動きも、PSC管理への個別化アプローチが普及するにつれて、技術革新と市場拡大の原動力となっています。これらの要因が相まって、PSC治療市場はダイナミックな成長を遂げ、患者の複雑なニーズに対応し、肝疾患分野の発展に寄与しています。

調査対象企業の例（全48件）

  • Acorda Therapeutics, Inc.
  • Dr. Falk Pharma GmbH
  • Durect Corporation
  • Gilead Sciences, Inc.
  • HighTide Therapeutics, Inc.
  • Immunic AG
  • Intercept Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • NGM Biopharmaceuticals Inc.
  • Novartis AG
  • Pliant Therapeutics
  • Sirnaomics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Pharmaceuticals（USA）Inc.;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26752

Global Primary Sclerosing Cholangitis Treatment Market to Reach US$220.1 Million by 2030

The global market for Primary Sclerosing Cholangitis Treatment estimated at US$185.7 Million in the year 2023, is expected to reach US$220.1 Million by 2030, growing at a CAGR of 2.5% over the analysis period 2023-2030. Oral Administration, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$169.5 Million by the end of the analysis period. Growth in the Parenteral Administration segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$50.6 Million While China is Forecast to Grow at 5.0% CAGR

The Primary Sclerosing Cholangitis Treatment market in the U.S. is estimated at US$50.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$43.9 Million by the year 2030 trailing a CAGR of 5.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Global Primary Sclerosing Cholangitis Treatment Market - Key Trends and Drivers Summarized

What Is Primary Sclerosing Cholangitis and How Is It Treated?

Primary Sclerosing Cholangitis (PSC) is a chronic, progressive liver disease characterized by inflammation and scarring of the bile ducts, which can lead to liver damage and eventual liver failure. The exact cause of PSC is unknown, but it is often associated with autoimmune disorders and has a strong correlation with inflammatory bowel disease (IBD). Symptoms of PSC can include jaundice, itching, abdominal pain, and fatigue, with the disease often progressing silently until significant liver damage occurs. Treatment for PSC primarily focuses on managing symptoms, slowing disease progression, and addressing complications. Medications such as ursodeoxycholic acid (UDCA) are commonly used to improve liver function and slow the progression of the disease. In cases where PSC leads to liver failure, a liver transplant may be considered as a definitive treatment option. However, due to the complexities of PSC and its association with other conditions, managing the disease requires a comprehensive, multidisciplinary approach tailored to the individual patient’s needs.

What Are the Latest Advances in Primary Sclerosing Cholangitis Treatment?

Recent advances in the treatment of Primary Sclerosing Cholangitis (PSC) have focused on improving patient outcomes through novel therapies and personalized treatment strategies. New research into the underlying mechanisms of PSC has led to the development of targeted therapies aimed at modulating the immune system and reducing inflammation within the bile ducts. Clinical trials are investigating the efficacy of drugs such as obeticholic acid, which has shown promise in reducing liver inflammation and fibrosis in patients with PSC. Additionally, advancements in the understanding of the genetic and molecular basis of PSC are paving the way for precision medicine approaches, allowing for more personalized treatment plans based on individual genetic profiles and disease characteristics. The role of combination therapies, integrating traditional medications with new agents, is also being explored to enhance treatment efficacy and manage complex cases of PSC. These developments represent a significant shift towards more effective and individualized treatment options for managing this challenging condition.

How Do Lifestyle Changes and Supportive Therapies Affect PSC Management?

In addition to pharmacological treatments, lifestyle modifications and supportive therapies play a crucial role in managing Primary Sclerosing Cholangitis (PSC). Dietary changes are often recommended to support liver health and manage symptoms, such as a low-fat diet to reduce the risk of malabsorption and nutrient deficiencies. Regular monitoring and management of associated conditions, such as inflammatory bowel disease (IBD), are essential for optimizing overall health and mitigating complications related to PSC. Supportive therapies, including the use of medications to manage itching, vitamin supplements, and treatments for complications like osteoporosis or diabetes, are also integral to comprehensive care. Patient education and psychological support are important aspects of managing a chronic disease like PSC, helping individuals cope with the emotional and physical challenges of the condition. Collaborative care involving hepatologists, gastroenterologists, dietitians, and other specialists ensures a holistic approach to managing PSC and improving quality of life for patients.

What Drives the Growth in the Primary Sclerosing Cholangitis Treatment Market?

The growth in the Primary Sclerosing Cholangitis (PSC) treatment market is driven by several factors. Advances in research and development are a major contributor, with ongoing studies focused on identifying new therapeutic targets and developing novel medications to address the underlying pathology of PSC. The increasing prevalence of PSC and the growing awareness of the disease among healthcare providers are fueling demand for improved treatment options. The rise in clinical trials and investment in drug development by pharmaceutical companies reflect the need for more effective therapies and better management strategies for PSC. Additionally, the expansion of healthcare access and the availability of specialized liver centers contribute to market growth by providing more patients with access to advanced treatments and multidisciplinary care. The push towards personalized medicine and precision treatments is also driving innovation and market expansion, as tailored approaches to PSC management become more prevalent. These factors collectively contribute to the dynamic growth of the PSC treatment market, addressing the complex needs of patients and advancing the field of hepatology.

Select Competitors (Total 48 Featured) -

  • Acorda Therapeutics, Inc.
  • Dr. Falk Pharma GmbH
  • Durect Corporation
  • Gilead Sciences, Inc.
  • HighTide Therapeutics, Inc.
  • Immunic AG
  • Intercept Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • NGM Biopharmaceuticals Inc.
  • Novartis AG
  • Pliant Therapeutics
  • Sirnaomics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Pharmaceuticals (USA) Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Primary Sclerosing Cholangitis Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Patient Population and Increased Disease Awareness Spurs Demand for Effective PSC Treatments
    • Advancements in Pharmacological Treatments Expands Addressable Market Opportunity for Primary Sclerosing Cholangitis Therapy
    • Integration of Novel Biologics and Targeted Therapies Drives Adoption of Innovative Treatment Options
    • Focus on Early Diagnosis and Personalized Medicine Generates Demand for Tailored PSC Treatment Strategies
    • Combination Therapies and Multimodal Approaches Strengthen Business Case for Comprehensive Treatment Solutions
    • Advancements in Monitoring and Diagnostics Enhance Treatment Outcomes
    • Growing Interest in Patient-Centric Care and Support Programs Generates New Market Opportunities for PSC Therapies
    • Expansion of Healthcare Access and Specialized Clinics in Emerging Markets Drives Demand for PSC Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Primary Sclerosing Cholangitis Treatment Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Primary Sclerosing Cholangitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Parenteral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • JAPAN
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • CHINA
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • EUROPE
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Primary Sclerosing Cholangitis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • FRANCE
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • GERMANY
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Primary Sclerosing Cholangitis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • INDIA
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Primary Sclerosing Cholangitis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Primary Sclerosing Cholangitis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
  • AFRICA
    • Primary Sclerosing Cholangitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Primary Sclerosing Cholangitis Treatment by Administration Route - Oral Administration, Parenteral Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Parenteral Administration and Other Administration Routes for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Primary Sclerosing Cholangitis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030

IV. COMPETITION